Trondheim, 5 May 2025 NORBIT today announces that segment PIR has received a new contract manufacturing order, valued at approximately NOK 125 million from a European client in the defence and security sector. “With the strengthened operational foundation built through strategic investments in capacity and competence, we are well positioned to serve as an industrial partner for this type of client, while at the same time scaling production of our own proprietary, tailored technology offered globally under t ...

Correction of the Dividend Ex-Date All other information remains unchanged ------------------------------------------------------------------ On 25 April 2025, the Annual General Meeting of Shareholders of Pieno Žvaigždės AB decided to allocate the Company’s profit for the year 2024 and to pay out EUR 0.14 dividend per share. Dividends will be paid to the shareholders who at the end of the tenth business day following the day of the Annual General Meeting that adopted a decision on dividend payment, i.e. on ...

Only two homes remain available in this boutique luxury home communityGREENVILLE, S.C., May 05, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the final opportunity to purchase a new home in its Wrenfield community in the Piedmont, South Carolina area. Wrenfield is a boutique luxury single-family home community featuring just 32 estate-sized home sites located 11 miles from downtown Greenville with convenient access to South Carolina Hi ...

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period.Oral presentation at DDW 2025 of clinical data from the anti-IL-7R mAb Lusvertikimab open-label extension of the phase 2 CoTikiS study in ulcerative colitis.1,2Full clinical data package for study demonstrates potential of a first-in-class monotherapy with a novel mechanism of action in chronic and inflammator ...

Expanded vertical reflects Five Star Bank’s commitment to supporting America’s food supply chain through trusted, relationship-driven financial servicesRANCHO CORDOVA, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank, has expanded its food and agribusiness vertical to serve clients nationwide. The vertical, now called Food, Agribusiness & Diversified Industries ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8 ...

Group 1 - The French Financial Markets Authority (AMF) published non-compliance decisions regarding three alternative buyout offers by Bolloré SE on 2 May 2025 [1] - The affected companies are Compagnie du Cambodge, Financière Moncey, and Société Industrielle et Financière de l'Artois [1] - Bolloré SE has chosen not to appeal these decisions in the Paris Court of Appeal [1]

Core Insights - AB Science announced new data from its phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS), which will be presented at the ENCALS annual meeting in June 2025, indicating masitinib's potential as a disease modifier [1][2] - The clinical benefit of masitinib is particularly pronounced in a subgroup of ALS patients prior to complete loss of function, supporting the rationale for a phase 3 confirmatory study [2] Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [3][4] - The company's lead compound, masitinib, is already registered for veterinary use and is being developed for human medicine across various fields including oncology and neurological diseases [4] Clinical Findings - New analyses show that masitinib reduces serum neurofilament light chain (NfL) levels, suggesting a decrease in neuronal damage and supporting its disease-modifying potential in ALS [1][2] - Subgroup analyses indicate significant treatment effects in ALS patients before complete loss of function, with notable improvements in clinical endpoints and a +12-month survival benefit [2]

RELEASE DISCLOSURE OF TRADING IN OWN SHARES FROM APRIL 28 TO MAY 2, 2025 In accordance with the authorization granted by the Shareholders’ Meeting in order to trade in own shares and pursuant to applicable law on share repurchases, Rexel declares the following purchases of its own shares from April 28 to May 2, 2025: Name of the issuerIdentity code of the issuer (Legal Entity Identifier)Day of transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted ave ...

Monthly information relating to the total number of shares and voting rights making-up the share capital Information mensuelle relative au nombre total d’actions et de droits de vote composant le capital social Article L. 233-8 II of the French Commercial code and article 223-16of the AMF General Regulation Article L. 233-8-II du Code de commerce et article 223-16 du Règlement général de l’AMF Name and address of the Company: Planisware SADénomination sociale de l’émetteur : 200 avenue de Paris92320 Châtill ...